Background On 9 September 2020, the French Competition Authority (the “FCA”) imposed a fine of € 444 million on Genentech, Novartis and Roche for abusing their collective dominant position on the market for the commercialisation of drugs for the treatment of age-related macular degeneration (AMD) (an eye condition). The FCA’s decision concerned two virtually-identical products developed and manufactured by Genentech (a subsidiary of Roche): (i) Avastin - a lower-priced product indicated for the treatment of certain forms of cancer, and (ii) Lucentis - a higher-priced product indicated for the treatment of certain eye diseases, including AMD. For commercialisation purposes, Genen- tech licensed Lucentis to Novartis (which owns 33.3% of Roche), whilst Avastin was to be commercialised by
The French Competition Authority fines 3 laboratories for abusive efforts to segment the market (Novartis / Roche / Genentech)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.